循环肿瘤细胞数字RNA特征预测乳腺癌早期治疗反应
该研究建立了一个17基因的循环肿瘤细胞(CTC)来源转录本数字特征,用于高灵敏度早期监测乳腺癌治疗反应。在局部乳腺癌前瞻性队列中,新辅助治疗3周期后CTC评分升高与手术残留病相关(P=0.047);在转移性乳腺癌队列中,基线CTC评分与总生存相关(P=0.02),治疗4周后持续CTC信号亦相关(P=0.01)。在ER阳性亚组中,内分泌治疗3周后CTC内ER信号未能抑制预测早期进展(P=0.008)。
要点
- CTC来源17基因数字RNA特征可早期监测局部和转移性乳腺癌治疗反应。
- 新辅助治疗3周期后CTC评分升高与手术残留病相关(P=0.047)。
- 内分泌治疗3周后CTC内ER信号未抑制预测ER阳性患者早期进展(P=0.008)。
核心结论
- CTC来源的数字RNA特征可实现无创药效学测量,有助于指导局部和晚期乳腺癌的治疗选择。
研究设计与样本
- 研究描述了从血液中富集的乳腺癌CTC来源转录本的17基因数字特征。
- 在局部乳腺癌前瞻性队列中评估新辅助治疗3周期后CTC评分与手术残留病的关系。
- 在转移性乳腺癌前瞻性队列中评估基线CTC评分及治疗4周后CTC信号与总生存的关系。
- 在ER阳性亚组中评估内分泌治疗3周后CTC内ER信号抑制与早期进展的关系。
主要发现
- 局部乳腺癌新辅助治疗3周期后CTC评分升高与手术残留病相关(P=0.047)。
- 转移性乳腺癌基线CTC评分与总生存相关(P=0.02)。
- 转移性乳腺癌治疗4周后持续CTC信号与总生存相关(P=0.01)。
- ER阳性亚组内分泌治疗3周后CTC内ER信号未能抑制预测早期进展(P=0.008)。
- CTC内药物难治性ER信号与ESR1突变部分重叠,提示获得性内分泌耐药机制多样。
临床怎么用
- CTC来源数字RNA特征可用于无创监测局部和转移性乳腺癌的治疗反应。
- 内分泌治疗早期CTC内ER信号未抑制可提示ER阳性患者可能早期进展。
- CTC-RNA特征评分可能帮助指导局部和晚期乳腺癌的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The multiplicity of new therapies for breast cancer presents a challenge for treatment selection. We describe a 17-gene digital signature of breast circulating tumor cell (CTC)-derived transcripts enriched from blood, enabling high-sensitivity early monitoring of response. In a prospective cohort of localized breast cancer, an elevated CTC score after three cycles of neoadjuvant therapy is associated with residual disease at surgery (P = 0.047). In a second prospective cohort with metastatic breast cancer, baseline CTC score correlates with overall survival (P = 0.02), as does persistent CTC signal after 4 weeks of treatment (P = 0.01). In the subset with estrogen receptor (ER)-positive disease, failure to suppress ER signaling within CTCs after 3 weeks of endocrine therapy predicts early progression (P = 0.008). Drug-refractory ER signaling within CTCs overlaps partially with presence of ESR1 mutations, pointing to diverse mechanisms of acquired endocrine drug resistance. Thus, CTC-derived digital RNA signatures enable noninvasive pharmacodynamic measurements to inform therapy in breast cancer.Significance: Digital analysis of RNA from CTCs interrogates treatment responses of both localized and metastatic breast cancer. Quantifying CTC-derived ER signaling during treatment identifies patients failing to respond to ER suppression despite having functional ESR1. Thus, noninvasive scoring of CTC-RNA signatures may help guide therapeutic choices in localized and advanced breast cancer. Cancer Discov; 8(10); 1286-99. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1195.
引用
- Kwan TT, Bardia A, Spring LM, et al. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov. 2018. PMID: 30104333. doi:10.1158/2159-8290.CD-18-0432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。